Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 29, 2024Journal of Diabetes and its ComplicationsOpen Access

Association of sodium glucose co-transporter-2 inhibitors with risk of diabetic ketoacidosis among hospitalized patients: A multicentre cohort study

View Full Paper
Ask AI
Bookmark
Share

Authors

SSShohinee SarmaBHBenazir Hodzic-SantorARAfsaneh Raissi

Discussion

Loading...

Member takes

Overview

Multicentre cohort study observes diabetic ketoacidosis risk in hospitalized patients receiving SGLT-2 inhibitors, highlighting inpatient safety surveillance.

Key Points

  • The investigation evaluates the potential risk of diabetic ketoacidosis among hospitalized patients receiving sodium glucose co-transporter-2 inhibitors during routine clinical care.
  • A multicentre cohort study framework was implemented across hospital networks to evaluate diabetic ketoacidosis incidence associated with therapeutic SGLT-2i exposure.
  • Evidence highlights the necessity of systematic clinical vigilance for diabetic ketoacidosis when administering sodium glucose co-transporter-2 inhibitors to acute inpatient cohorts.

Cite This Study

Sarma et al. (2024) studied this question.

synapsesocial.com/papers/68e5ea28b6db64358757e8b6https://doi.org/10.1016/j.jdiacomp.2024.108827
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1914-P: Association of Sodium–Glucose Cotransporter 2 Inhibitors with Risk of Diabetic Ketoacidosis among Hospitalized Patients—A Multicentre Cohort Study2024
  2. 2Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitor-Related Euglycemic Diabetic Ketoacidosis: A Case Series2024 · 3 citations
  3. 3Clinical Severity of Diabetic Ketoacidosis by SGLT2 Inhibitors Use: A Retrospective Observational Study2026
  4. 4Balancing Risks and Benefits: Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis2024 · 2 citations
  5. 5Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis2020 · 184 citations